Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326131 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00326131 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 6 participants.
The verdict
NCT00326131, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.
Interventions
- DRUG Oral Taxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326131
The ClinicalTrials.gov registry entry for NCT00326131 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oral Taxane is the first listed.
NCT00326131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326131 about?
NCT00326131 is a clinical study titled "A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer". The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-275183 in your blood, study the safety of the drug, and to see what effects it has on your cancer.
What is the current status of trial NCT00326131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00326131?
The interventions under investigation include: Oral Taxane (DRUG).
Who is sponsoring clinical trial NCT00326131?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.